Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials (Q29622947)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

0 references

1 reference

Welsh P

4

0 references

John Kjekshus

23

object named as

Kjekshus J

1 reference

30 April 2017

13

Stott DJ

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

author name string

Sattar N

1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Preiss D

2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Murray HM

3

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

de Craen AJ

6

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Seshasai SR

7

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

McMurray JJ

8

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Freeman DJ

9

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Jukema JW

10

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Macfarlane PW

11

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Packard CJ

12

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Westendorp RG

14

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Shepherd J

15

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Davis BR

16

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Pressel SL

17

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Marchioli R

18

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Marfisi RM

19

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Maggioni AP

20

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Tavazzi L

21

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Tognoni G

22

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Pedersen TR

24

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Cook TJ

25

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Gotto AM

26

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Clearfield MB

27

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Downs JR

28

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Nakamura H

29

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Ohashi Y

30

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Mizuno K

31

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Ray KK

32

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Ford I

33

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Buckley BM

5

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

language of work or name

1 reference

30 April 2017

publication date

27 February 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

volume

375

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

page(s)

735-42

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

issue

9716

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

30 April 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

The safety of statins in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Rosuvastatin in older patients with systolic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Lipid lowering for primary prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

High-dose atorvastatin after stroke or transient ischemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Clinical risk factors, DNA variants, and the development of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Statin modulates insulin signaling and insulin resistance in liver and muscle of rats fed a high-fat diet

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Effect of pravastatin on the development of diabetes and adiponectin production

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961965-6

7 January 2021

10.1016/S0140-6736(09)61965-6

Identifiers

DOI

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

30 April 2017

Consolidated OpenCitations Corpus – April 2017

442187

442187

1 reference

Consolidated OpenCitations Corpus – April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20167359

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017